MAXION-WHEELS
10.9.2019 10:02:10 CEST | Business Wire | Press release
Maxion Wheels, the world’s largest wheel manufacturer, announced today it is collaborating with ZF OPENMATICS to develop the industry’s first, fully-integrated wheel connectivity solution. Initially, targeting the commercial vehicle market, the multiservice sensor will capture, analyze and broadcast key data such as tire pressure and temperature, wheel load and other wheel and tire performance metrics to drivers, fleet managers, and infrastructure authorities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190910005112/en/
“As a result of the unique load sensor attached to the wheel, the tire and wheel information collected and communicated via the Smart Wheel Connectivity Solution will enable a variety of new safety and efficiency use and business cases,” said Pieter Klinkers, Chief Executive Officer, Maxion Wheels. “By partnering with ZF OPENMATICS we combine our wheel leadership with their intelligent sensing and telematics expertise to offer an integrated mechanical and sensing solution that will help prevent potentially dangerous and costly tire and wheel-end failures, as well as, provide drivers and fleet managers with critical vehicle performance data needed to optimize their business.”
“ZF has the benefit of years of experience with wireless communication like BLE (Bluetooth Low Energy). We are now combining this expertise with that of Maxion to create the world’s first fully integrated battery-powered Wheel TAG sensor that add important functionalities beyond tire pressure monitoring. The benefits of real-time wheel monitoring solutions are being extended to tire life and optimal tire performance. This is another step in the direction of improving road safety, driving comfort and cost efficiency,” said Thomas Rösch, Managing Director ZF OPENMATICS.
The Smart Wheel Connectivity Solution combines Maxion Wheels’ MaxSmart® wheel sensor technology with ZF OPENMATICS’ integrated TAG sensor platform. Mounted directly to each wheel rim of the vehicle, the durable Bluetooth tags track humidity, tire temperature, air pressure and vehicle load as well as wheel position, speed and vibration across nine axis. Information is collected real time and wirelessly transmitted to the vehicle’s telematics onboard unit before being transferred to the ZF Cloud. The data can then be read and analyzed via PC, smart devices or sent to a 3rd party system of the customer’s choice. By fully integrating each different data sensor into one easy-to-use TAG, ZF and Maxion offer unparalleled, true 360° monitoring possibilities.
This fully-integrated system can be installed on virtually all kinds of commercial vehicles and even in agricultural machinery. It provides unique, at-first glance insights, helping to enhance road safety and decrease costs. This makes it highly valuable not only for fleet operators but also mobility providers for autonomous driving solutions.
The new partnership presents its first prototype during the 2019 IAA motor show with the goal to complete its feasibility studies during the first half of 2020, followed by real-world testing and validation.
ABOUT MAXION WHEELS
Maxion Wheels, a division of IOCHPE-MAXION S.A., is a leading wheel manufacturer for passenger cars, light trucks, buses, commercial trucks and trailers. The Company also produces wheels for agriculture, as well as other off-highway applications. With more than 100 years of wheel-making experience and 10,000 employees globally, Maxion Wheels is the world's largest wheel manufacturer, producing nearly 60 million wheels per year. It serves its global OEM customers from 31 locations in 15 countries on five continents, including state-of-the-art technical centers in the Americas, Europe and Asia. To learn more, please visit Maxion Wheels’ website at www.maxionwheels.com .
ABOUT ZF FRIEDRICHSHAFEN AG
ZF is a global technology company and supplies systems for passenger cars, commercial vehicles and industrial technology, enabling the next generation of mobility. With its comprehensive technology portfolio, the company offers integrated solutions for established vehicle manufacturers, mobility providers and start-up companies in the fields of transportation and mobility. ZF continually enhances its systems in the areas of digital connectivity and automation in order to allow vehicles to see, think and act.
In 2018, ZF achieved sales of €36.9 billion. The company has a global workforce of 149,000 with approximately 230 locations in 40 countries. ZF invests over six percent of its sales in research and development annually.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005112/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom